by MM360 Staff | Mar 15, 2026 | Publications
Cancers (Basel). 2026 Feb 26;18(5):755. doi: 10.3390/cancers18050755. ABSTRACT Background/Objectives: Ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma is typically administered inpatient (IP) to monitor for cytokine release syndrome (CRS)...
by MM360 Staff | Mar 14, 2026 | Publications
Ann Med. 2026 Dec;58(1):2641930. doi: 10.1080/07853890.2026.2641930. Epub 2026 Mar 12. ABSTRACT BACKGROUND: Elotuzumab, an anti-SLAMF7 monoclonal antibody for multiple myeloma (MM), lacks a comprehensive safety profile from meta-analysis. METHODS: We systematically...
by MM360 Staff | Mar 8, 2026 | Publications
Eur J Nucl Med Mol Imaging. 2026 Mar 7. doi: 10.1007/s00259-026-07830-5. Online ahead of print. NO ABSTRACT PMID:41792563 | DOI:10.1007/s00259-026-07830-5
by MM360 Staff | Mar 3, 2026 | Publications
Front Pharmacol. 2026 Feb 12;16:1687718. doi: 10.3389/fphar.2025.1687718. eCollection 2025. ABSTRACT BACKGROUND: Cluster of differentiation 38 (CD38) monoclonal antibodies, including daratumumab and isatuximab, have demonstrated clinical activity in relapsed or...
by MM360 Staff | Feb 28, 2026 | Publications
Cancers (Basel). 2026 Feb 19;18(4):686. doi: 10.3390/cancers18040686. ABSTRACT Background: B-cell maturation antigen (BCMA) directed therapies have transformed the treatment landscape for relapsed or refractory multiple myeloma (RRMM). Soluble BCMA (sBCMA), a...
by MM360 Staff | Feb 19, 2026 | Publications
Leukemia. 2026 Feb 17. doi: 10.1038/s41375-026-02880-y. Online ahead of print. NO ABSTRACT PMID:41703031 | DOI:10.1038/s41375-026-02880-y
